Search

Your search keyword '"Stanzione, Brigida"' showing total 30 results
Start Over Author "Stanzione, Brigida"
30 results on '"Stanzione, Brigida"'

6. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

Author

Bonotto, Marta, Gerratana, Lorenzo, Di Maio, Massimo, De Angelis, Carmine, Cinausero, Marika, Moroso, Stefano, Milano, Monica, Stanzione, Brigida, Gargiulo, Piera, Iacono, Donatella, Minisini, Alessandro Marco, Mansutti, Mauro, Fasola, Gianpiero, De Placido, Sabino, Arpino, Grazia, and Puglisi, Fabio

Published
2017
Full Text
View/download PDF

16. Manual of Cardio-oncology Cardiovascular Care in the Cancer Patient

Author

Bidoli, Ettore, Serraino, Diego, Catino, Annamaria, Misino, Andrea, Lagroscino, Antonio, Montagna, Elisabetta Sara, Galetta, Domenico, Tralongo, Paolo, Lestuzzi, Chiara, Furlanello, Francesco, Bisceglia, Irma, Maurea, Nicola, Parrini, Iris, Barni, Sandro, Petrelli, Fausto, Bassani, Barbara, Bruno, Antonino, Macrì, Nicoletta, Corradino, Paola, Noonan, Douglas M., Albini, Adriana, Oliva, Stefano, Monte, Ines, Cardinale, Daniela, Labianca, Roberto, Iliescu, Cezar, Ghiliardi, Laura, Garozzo, Maurizio, Clementi, Anna, Battaglia, Giorgio, Nohria, Anju, Asteggiano, Riccardo, Vellario, Paola, Pessano, Sara, Morsellino, Vera, Haupt, Riccardo, Fratino, Lucia, Beretta, Massimiliano, Derchi, Maria, Stanzione, Brigida, Natale, Annalisa, Santarone, Stella, Di Bartolomeo, Paolo, Bardonaro, Sebastiano, Tralongo, Antonino Carmelo, Pino, Paolo Giuseppe, Roldan, Carlos, Risso, Stefania, Thiene, Gaetano, Valente, Marialuisa, Basso, Cristina, Aquaro, Giovanni Donato, Urbani, Martina, Borsatti, Eugenio, Baresic, Tanja, Santini, Francesco, Viganò, Gaia, Salsano, Antonio, Salvador, Loris, De Paoli, Antonino, Miolo, Gian Maria, Buonadonna, Angela, Santeufemia, Davide, Ferraù, Francesco, Spallarossa, Paolo, Sarocchi, Matteo, Thomas, Olivia Maria, and Caggegi, Maria Agnese

Published
2017

18. It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature

Author

Pensabene, Matilde, primary, Stanzione, Brigida, additional, Cerillo, Ivana, additional, Ciancia, Giuseppe, additional, Cozzolino, Immacolata, additional, Ruocco, Raffaella, additional, Condello, Caterina, additional, Di Lorenzo, Giuseppe, additional, Giuliano, Mario, additional, Forestieri, Valeria, additional, Arpino, Grazia, additional, De Placido, Sabino, additional, and Lauria, Rossella, additional

Published
2018
Full Text
View/download PDF

20. Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine

Author

DE ANGELIS, CRISTINA, MILANO, MONICA, STANZIONE, BRIGIDA, FORESTIERI, VALERIA, LAURIA, ROSSELLA, PENSABENE, MATILDE, D'ARCO, FELICE, DE PLACIDO, SABINO, ARPINO, GRAZIA, Gargiulo, P, DE ANGELIS CARMINE, DE ANGELIS, Cristina, Milano, Monica, Gargiulo, P, Stanzione, Brigida, Forestieri, Valeria, Lauria, Rossella, Pensabene, Matilde, D'Arco, Felice, DE PLACIDO, Sabino, Arpino, Grazia, and DE ANGELIS, Carmine

Published
2013

24. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to prior therapy.

Author

De Angelis, Carmine, primary, Cerillo, Ivana, additional, Ruocco, Raffaella, additional, Bruzzese, Dario, additional, Forestieri, Valeria, additional, Lauria, Rossella, additional, Stanzione, Brigida, additional, Paciolla, Immacolata, additional, De Laurentiis, Michelino, additional, De Placido, Sabino, additional, and Arpino, Grazia, additional

Published
2013
Full Text
View/download PDF

27. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

Author

Grazia Arpino, Fabio Puglisi, Marta Bonotto, Massimo Di Maio, Gianpiero Fasola, Lorenzo Gerratana, S. Moroso, Mauro Mansutti, Sabino De Placido, Donatella Iacono, Monica Milano, Carmine De Angelis, Marika Cinausero, Brigida Stanzione, Alessandro Marco Minisini, Piera Gargiulo, Bonotto, Marta, Gerratana, Lorenzo, Di Maio, Massimo, DE ANGELIS, Carmine, Cinausero, Marika, Moroso, Stefano, Milano, Monica, Stanzione, Brigida, Gargiulo, Piera, Iacono, Donatella, Minisini, Alessandro Marco, Mansutti, Mauro, Fasola, Gianpiero, DE PLACIDO, Sabino, Arpino, Grazia, and Puglisi, Fabio

Subjects
0301 basic medicine, Oncology, Multivariate analysis, Receptor, ErbB-2, medicine.medical_treatment, Hormone antagonist, Antineoplastic Agent, Metastatic breast neoplasms, 0302 clinical medicine, Retrospective Studie, Age Factor, Metastatic breast neoplasm, Neoplasm Metastasis, Treatment outcome, Multivariate Analysi, Chemotherapy, Decision making, Drug therapy, education.field_of_study, Age Factors, General Medicine, Middle Aged, Metastatic breast cancer, Neoplasm Metastasi, 030220 oncology & carcinogenesis, Female, Breast Neoplasm, Human, medicine.medical_specialty, Population, Antineoplastic Agents, Breast Neoplasms, Disease-Free Survival, 03 medical and health sciences, Hormone Antagonists, Pharmacotherapy, Internal medicine, medicine, Humans, Propensity Score, education, Aged, Retrospective Studies, business.industry, Retrospective cohort study, medicine.disease, Surgery, Hormone Antagonist, 030104 developmental biology, Multivariate Analysis, Propensity score matching, business
Abstract

Background According to current guidelines, endocrine therapy (ET) is recommended as first-line treatment of luminal-like metastatic breast cancer (MBC), whereas chemotherapy (CT) should be considered in presence of life-threatening disease. In daily practice, CT is often used outside of this clinical circumstance. Factors influencing first-line choice and the relative impact on outcome are unknown. Methods A consecutive series of luminal-like HER2-negative MBC patients treated from 2004 to 2014 was analyzed to test the association of disease- and patient-related factors with the choice of first-line treatment (ET vs. CT). A propensity score method was used to estimate impact of first-line strategy on outcome. Results Of 604 consecutive luminal-like MBC patients identified, 158 cases were excluded due to unknown or positive HER2-status. Among 446 HER2-negative cases, 171 (38%) received first-line CT. On multivariate analysis, the only factors significantly associated with lower CT use were old age (OR 0.25, 95%C.I. 0.13–0.49) or presence of bone metastases only (OR 0.26, 95%C.I. 0.13–0.53). In propensity score matched population, no differences were observed between CT and ET as first-line treatment either in terms of overall survival (37.5 months and 33.4 months respectively, log-rank test, P = 0.62) or progression-free survival (13.3 months and 9.9 months respectively, log-rank test, P = 0.92). Conclusions High percentage of patients with luminal-like MBC received CT as first-line therapy in real-life. The choice was mainly driven by age and site of metastases. With the limitations of a non-randomized comparison, no differences on patients' outcome were observed depending on the first-line strategy.

Published
2017

28. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications

Author

Tiziana Perin, Lara Alessandrini, Vincenzo Canzonieri, Massimiliano Berretta, Carla Cavaliere, Luca Balestreri, Gaetano Facchini, Brigida Stanzione, Berretta, Massimiliano, Cavaliere, Carla, Alessandrini, Lara, Stanzione, Brigida, Facchini, Gaetano, Balestreri, Luca, Perin, Tiziana, and Canzonieri, Vincenzo

Subjects
Oncology, medicine.medical_specialty, Carcinoma, Hepatocellular, medicine.medical_treatment, tissue marker, Review, Liver transplantation, Malignancy, hepatocellular carcinoma, cholangiocarcinoma, serum markers, tissue markers, prognosis, metastasis, Metastasis, Primary sclerosing cholangitis, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Biomarkers, Tumor, medicine, Humans, Survival rate, Tumor marker, serum marker, business.industry, Liver Neoplasms, Cancer, Cholangiocarcinoma, Hepatocellular carcinoma, Prognosis, Serum markers, Tissue markers, medicine.disease, Surgery, Bile Duct Neoplasms, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, business, prognosi
Abstract

// Massimiliano Berretta 1 , Carla Cavaliere 2 , Lara Alessandrini 3,* , Brigida Stanzione 1,* , Gaetano Facchini 4 , Luca Balestreri 5 , Tiziana Perin 3 and Vincenzo Canzonieri 3 1 Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy 2 Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto Taranto, Italy 3 Division of Pathology, National Cancer Institute, Aviano (PN), Italy 4 Department of Medical Oncology, National Cancer Institute, “G. Pascale” Foundation, Naples, Italy 5 Department of Radiology, National Cancer Institute, Aviano (PN), Italy * These authors have contributed equally to this work Correspondence to: Massimiliano Berretta, email: // Keywords : hepatocellular carcinoma, cholangiocarcinoma, serum markers, tissue markers, prognosis, metastasis Received : September 16, 2016 Accepted : October 28, 2016 Published : December 14, 2016 Abstract HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis –PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.

Published
2017

29. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.

Author

Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, and Canzonieri V

Subjects
Bile Duct Neoplasms mortality, Carcinoma, Hepatocellular mortality, Cholangiocarcinoma mortality, Humans, Liver Neoplasms mortality, Prognosis, Bile Duct Neoplasms pathology, Biomarkers, Tumor analysis, Carcinoma, Hepatocellular pathology, Cholangiocarcinoma pathology, Liver Neoplasms pathology
Abstract

HCC represents the sixth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence, treatment options for advanced HCC remain limited and unsuccessful, resulting in a poor prognosis. Despite the major advances achieved in the diagnostic management of HCC, only one third of the newly diagnosed patients are presently eligible for curative treatments. Advances in technology and an increased understanding of HCC biology have led to the discovery of novel biomarkers. Improving our knowledge about serum and tissutal markers could ultimately lead to an early diagnosis and better and early treatment strategies for this deadly disease. Serum biomarkers are striking potential tools for surveillance and early diagnosis of HCC thanks to the non-invasive, objective, and reproducible assessments they potentially enable. To date, many biomarkers have been proposed in the diagnosis of HCC. Cholangiocarcinoma (CCA) is an aggressive malignancy, characterized by early lymph node involvement and distant metastasis, with 5-year survival rates of 5%-10%. The identification of new biomarkers with diagnostic, prognostic or predictive value is especially important as resection (by surgery or combined with a liver transplant) has shown promising results and novel therapies are emerging. However, the relatively low incidence of CCA, high frequency of co-existing cholestasis or cholangitis (primary sclerosing cholangitis -PSC- above all), and difficulties with obtaining adequate samples, despite advances in sampling techniques and in endoscopic visualization of the bile ducts, have complicated the search for accurate biomarkers. In this review, we attempt to analyze the existing literature on this argument.

Published
2017
Full Text
View/download PDF

30. Multiple metachronus proliferative fasciitis occurring in different anatomic regions: a case report and review of the literature.

Author

Stanzione B, Cozzolino I, Arpino G, Vigliar E, Virginia SF, and Zeppa P

Subjects
Adult, Biomarkers analysis, Connective Tissue Diseases metabolism, Connective Tissue Diseases surgery, Fasciitis metabolism, Fasciitis surgery, Female, Forearm, Humans, Immunohistochemistry, Magnetic Resonance Imaging, Myofibroblasts chemistry, Orbital Diseases metabolism, Orbital Diseases surgery, Recurrence, Time Factors, Treatment Outcome, Cell Proliferation, Connective Tissue Diseases pathology, Fasciitis pathology, Myofibroblasts pathology, Orbital Diseases pathology
Abstract

Proliferative fasciitis is a benign lesion that usually has a self-limited course and rarely recurs after excision. In the literature, the multifocal occurrence of PF in different anatomic sites has not been reported so far. In this report, we describe the clinical case of a 30-year-old woman with two metachronous proliferative fasciitis occurring firstly in the orbit and, after 18 months, in the forearm; we also review the available literature on this topic, outlining guidelines for therapy and the follow-up of these patients., (Copyright © 2012 Elsevier GmbH. All rights reserved.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results